18F-sodium fluoride PET/CT in oncology: An atlas of SUVs

Nathanael Sabbah, Tatianie Jackson, Camila Mosci, Mehran Jamali, Ryogo Minamimoto, Andrew Quon, Erik Mittra, Andrei Iagaru

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to analyze the distribution of 18F Sodium Fluoride (18F-NaF) uptake in the normal skeleton, benign and malignant bone lesions, and extraskeletal tissues, using semiquantitative SUV measurements. Patients andMethods: We retrospectively analyzed data from 129 patients who had 18F-NaF PET/CT at our institution for an oncological diagnosis between 2007 and 2014. There were 99 men and 30 women, 19 to 90 years old (mean [SD], 61.5 [15.5]). The range, average, and SD of SUV were measured for normal bone and extraskeletal tissues uptake for the entire patient population. A separate statistical analysis was performed to compare group A, which corresponds to the population of patient with no 18F-NaF-avid metastatic lesions, and group B, which corresponds to the population of patient with 18F-NaF-avid metastatic lesions. We also measured SUVmax and SUVmean for bony metastases and degenerative changes Results: The PET/CT images were acquired at 30 to 169 minutes (mean [SD], 76.5 [22.8]) after injection of 3.9 to 13.6 mCi (mean [SD], 7.3 [2.4]) of 18F-NaF. The range and mean (SD) of SUVmax for 18F-NaF-avid metastasis were 4.5 to 103.3 and 25.9 (16.6) and for 18F-NaF-avid degenerative changes were 3.3 to 52.1 and 16.5 (7.9), respectively. Conclusions: Various skeletal sites have different normal SUVs. Skeletal metastases have different SUVs when compared with benign findings such as degenerative changes.

Original languageEnglish (US)
Pages (from-to)e228-e231
JournalClinical Nuclear Medicine
Volume40
Issue number4
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Sodium Fluoride
Atlases
Neoplasm Metastasis
Population
Bone and Bones
Skeleton
Injections

Keywords

  • F-NaF
  • Atlas
  • PET/CT
  • SUV

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Sabbah, N., Jackson, T., Mosci, C., Jamali, M., Minamimoto, R., Quon, A., ... Iagaru, A. (2015). 18F-sodium fluoride PET/CT in oncology: An atlas of SUVs. Clinical Nuclear Medicine, 40(4), e228-e231. https://doi.org/10.1097/RLU.0000000000000633

18F-sodium fluoride PET/CT in oncology : An atlas of SUVs. / Sabbah, Nathanael; Jackson, Tatianie; Mosci, Camila; Jamali, Mehran; Minamimoto, Ryogo; Quon, Andrew; Mittra, Erik; Iagaru, Andrei.

In: Clinical Nuclear Medicine, Vol. 40, No. 4, 01.01.2015, p. e228-e231.

Research output: Contribution to journalArticle

Sabbah, N, Jackson, T, Mosci, C, Jamali, M, Minamimoto, R, Quon, A, Mittra, E & Iagaru, A 2015, '18F-sodium fluoride PET/CT in oncology: An atlas of SUVs', Clinical Nuclear Medicine, vol. 40, no. 4, pp. e228-e231. https://doi.org/10.1097/RLU.0000000000000633
Sabbah N, Jackson T, Mosci C, Jamali M, Minamimoto R, Quon A et al. 18F-sodium fluoride PET/CT in oncology: An atlas of SUVs. Clinical Nuclear Medicine. 2015 Jan 1;40(4):e228-e231. https://doi.org/10.1097/RLU.0000000000000633
Sabbah, Nathanael ; Jackson, Tatianie ; Mosci, Camila ; Jamali, Mehran ; Minamimoto, Ryogo ; Quon, Andrew ; Mittra, Erik ; Iagaru, Andrei. / 18F-sodium fluoride PET/CT in oncology : An atlas of SUVs. In: Clinical Nuclear Medicine. 2015 ; Vol. 40, No. 4. pp. e228-e231.
@article{501e0ad716a145f9bf1ed08a98bdaf6a,
title = "18F-sodium fluoride PET/CT in oncology: An atlas of SUVs",
abstract = "Purpose: The purpose of this study was to analyze the distribution of 18F Sodium Fluoride (18F-NaF) uptake in the normal skeleton, benign and malignant bone lesions, and extraskeletal tissues, using semiquantitative SUV measurements. Patients andMethods: We retrospectively analyzed data from 129 patients who had 18F-NaF PET/CT at our institution for an oncological diagnosis between 2007 and 2014. There were 99 men and 30 women, 19 to 90 years old (mean [SD], 61.5 [15.5]). The range, average, and SD of SUV were measured for normal bone and extraskeletal tissues uptake for the entire patient population. A separate statistical analysis was performed to compare group A, which corresponds to the population of patient with no 18F-NaF-avid metastatic lesions, and group B, which corresponds to the population of patient with 18F-NaF-avid metastatic lesions. We also measured SUVmax and SUVmean for bony metastases and degenerative changes Results: The PET/CT images were acquired at 30 to 169 minutes (mean [SD], 76.5 [22.8]) after injection of 3.9 to 13.6 mCi (mean [SD], 7.3 [2.4]) of 18F-NaF. The range and mean (SD) of SUVmax for 18F-NaF-avid metastasis were 4.5 to 103.3 and 25.9 (16.6) and for 18F-NaF-avid degenerative changes were 3.3 to 52.1 and 16.5 (7.9), respectively. Conclusions: Various skeletal sites have different normal SUVs. Skeletal metastases have different SUVs when compared with benign findings such as degenerative changes.",
keywords = "F-NaF, Atlas, PET/CT, SUV",
author = "Nathanael Sabbah and Tatianie Jackson and Camila Mosci and Mehran Jamali and Ryogo Minamimoto and Andrew Quon and Erik Mittra and Andrei Iagaru",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/RLU.0000000000000633",
language = "English (US)",
volume = "40",
pages = "e228--e231",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - 18F-sodium fluoride PET/CT in oncology

T2 - An atlas of SUVs

AU - Sabbah, Nathanael

AU - Jackson, Tatianie

AU - Mosci, Camila

AU - Jamali, Mehran

AU - Minamimoto, Ryogo

AU - Quon, Andrew

AU - Mittra, Erik

AU - Iagaru, Andrei

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: The purpose of this study was to analyze the distribution of 18F Sodium Fluoride (18F-NaF) uptake in the normal skeleton, benign and malignant bone lesions, and extraskeletal tissues, using semiquantitative SUV measurements. Patients andMethods: We retrospectively analyzed data from 129 patients who had 18F-NaF PET/CT at our institution for an oncological diagnosis between 2007 and 2014. There were 99 men and 30 women, 19 to 90 years old (mean [SD], 61.5 [15.5]). The range, average, and SD of SUV were measured for normal bone and extraskeletal tissues uptake for the entire patient population. A separate statistical analysis was performed to compare group A, which corresponds to the population of patient with no 18F-NaF-avid metastatic lesions, and group B, which corresponds to the population of patient with 18F-NaF-avid metastatic lesions. We also measured SUVmax and SUVmean for bony metastases and degenerative changes Results: The PET/CT images were acquired at 30 to 169 minutes (mean [SD], 76.5 [22.8]) after injection of 3.9 to 13.6 mCi (mean [SD], 7.3 [2.4]) of 18F-NaF. The range and mean (SD) of SUVmax for 18F-NaF-avid metastasis were 4.5 to 103.3 and 25.9 (16.6) and for 18F-NaF-avid degenerative changes were 3.3 to 52.1 and 16.5 (7.9), respectively. Conclusions: Various skeletal sites have different normal SUVs. Skeletal metastases have different SUVs when compared with benign findings such as degenerative changes.

AB - Purpose: The purpose of this study was to analyze the distribution of 18F Sodium Fluoride (18F-NaF) uptake in the normal skeleton, benign and malignant bone lesions, and extraskeletal tissues, using semiquantitative SUV measurements. Patients andMethods: We retrospectively analyzed data from 129 patients who had 18F-NaF PET/CT at our institution for an oncological diagnosis between 2007 and 2014. There were 99 men and 30 women, 19 to 90 years old (mean [SD], 61.5 [15.5]). The range, average, and SD of SUV were measured for normal bone and extraskeletal tissues uptake for the entire patient population. A separate statistical analysis was performed to compare group A, which corresponds to the population of patient with no 18F-NaF-avid metastatic lesions, and group B, which corresponds to the population of patient with 18F-NaF-avid metastatic lesions. We also measured SUVmax and SUVmean for bony metastases and degenerative changes Results: The PET/CT images were acquired at 30 to 169 minutes (mean [SD], 76.5 [22.8]) after injection of 3.9 to 13.6 mCi (mean [SD], 7.3 [2.4]) of 18F-NaF. The range and mean (SD) of SUVmax for 18F-NaF-avid metastasis were 4.5 to 103.3 and 25.9 (16.6) and for 18F-NaF-avid degenerative changes were 3.3 to 52.1 and 16.5 (7.9), respectively. Conclusions: Various skeletal sites have different normal SUVs. Skeletal metastases have different SUVs when compared with benign findings such as degenerative changes.

KW - F-NaF

KW - Atlas

KW - PET/CT

KW - SUV

UR - http://www.scopus.com/inward/record.url?scp=84925423901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925423901&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000633

DO - 10.1097/RLU.0000000000000633

M3 - Article

C2 - 25546225

AN - SCOPUS:84925423901

VL - 40

SP - e228-e231

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 4

ER -